C Wang1, G Young2. 1. Keck School of Medicine, USC, Los Angeles, CA, USA. 2. Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Abstract
INTRODUCTION: Although clinical trials have demonstrated extended half-life (EHL) VIII and IX fusion proteins to be safe and efficacious in patients with haemophilia A and B, studies on real-world clinical application have not been performed. AIM: To retrospectively examine the real-world experience of rFVIII Fc and rFIX Fc in patients. METHODS: A retrospective review of existing medical records of patients with haemophilia A or haemophilia B who had been prescribed rFVIII Fc or rFIX Fc was conducted from the Children's Hospital Los Angeles Haemostasis and Thrombosis Centre database. RESULTS: A total of 36 male subjects enroled in the study (17 patients with haemophilia A and 19 patients with haemophilia B; 0-18 years of age, N = 27; >18 years of age, N = 9). Patients had a reduction of their ABR and AJBR following initiation of EHL factors. For patients with haemophilia A, the ABR and ABJR fell from 2.3 and 1.8 to 1.3 and 0.71, respectively. For patients with haemophilia B, the ABR and ABJR fell from 2.5 and 2.1 to 0.82 and 0.37, respectively. Five of 36 patients reverted from EHL back to standard half-life (SHL) factor treatment. Overall, treatment with EHL factors reduced factor consumption by nearly half compared to treatment with SHL factors in patients with haemophilia B. CONCLUSION: This study demonstrates the largely successful transition of 36 patients from SHL to EHL factor products.
INTRODUCTION: Although clinical trials have demonstrated extended half-life (EHL) VIII and IX fusion proteins to be safe and efficacious in patients with haemophilia A and B, studies on real-world clinical application have not been performed. AIM: To retrospectively examine the real-world experience of rFVIII Fc and rFIX Fc in patients. METHODS: A retrospective review of existing medical records of patients with haemophilia A or haemophilia B who had been prescribed rFVIII Fc or rFIX Fc was conducted from the Children's Hospital Los Angeles Haemostasis and Thrombosis Centre database. RESULTS: A total of 36 male subjects enroled in the study (17 patients with haemophilia A and 19 patients with haemophilia B; 0-18 years of age, N = 27; >18 years of age, N = 9). Patients had a reduction of their ABR and AJBR following initiation of EHL factors. For patients with haemophilia A, the ABR and ABJR fell from 2.3 and 1.8 to 1.3 and 0.71, respectively. For patients with haemophilia B, the ABR and ABJR fell from 2.5 and 2.1 to 0.82 and 0.37, respectively. Five of 36 patients reverted from EHL back to standard half-life (SHL) factor treatment. Overall, treatment with EHL factors reduced factor consumption by nearly half compared to treatment with SHL factors in patients with haemophilia B. CONCLUSION: This study demonstrates the largely successful transition of 36 patients from SHL to EHL factor products.
Authors: Amit Chhabra; Dean Spurden; Patrick F Fogarty; Bartholomew J Tortella; Emily Rubinstein; Simon Harris; Andreas M Pleil; Jennifer Mellor; Jonathan de Courcy; José Alvir Journal: Blood Coagul Fibrinolysis Date: 2020-04 Impact factor: 1.061
Authors: Cihan Ay; Clemens Feistritzer; Joachim Rettl; Gerhard Schuster; Anna Vavrovsky; Leonard Perschy; Ingrid Pabinger Journal: Sci Rep Date: 2021-06-21 Impact factor: 4.379
Authors: Beatrice Nolan; Johnny Mahlangu; Ingrid Pabinger; Guy Young; Barbara A Konkle; Chris Barnes; Keiji Nogami; Elena Santagostino; K John Pasi; Liane Khoo; Bent Winding; Huixing Yuan; Joachim Fruebis; Dan Rudin; Johannes Oldenburg Journal: Haemophilia Date: 2020-03-30 Impact factor: 4.287
Authors: Marissa J M Traets; Kathelijn Fischer; Nanda Uitslager; Paul R van der Valk; Idske C L Kremer Hovinga; Lize F D van Vulpen; Roger E G Schutgens Journal: TH Open Date: 2020-11-08
Authors: Maria Elisa Mancuso; Mark T Reding; Claude Negrier; Bryce A Kerlin; Savita Rangarajan; Mindy L Simpson Journal: Thromb Haemost Date: 2020-12-09 Impact factor: 6.681